Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Revenue of Exact Sciences Corporation (EXAS)
Revenue in 2023 (TTM): $2.5 B
According to Exact Sciences Corporation's latest financial reports the company's current revenue (TTM) is $2.5 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Exact Sciences Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.5 B | $1.85 B | $41.88 M | $-201,746,000 | $-204,149,000 |
| 2022 | $2.08 B | $1.51 B | $-386,739,000 | $-632,570,000 | $-623,506,000 |
| 2021 | $1.77 B | $1.31 B | $-617,729,000 | $-842,506,000 | $-595,625,000 |
| 2020 | $1.49 B | $1.14 B | $-632,859,000 | $-857,105,000 | $-848,533,000 |
| 2019 | $876.29 M | $659.58 M | $-217,747,000 | $-268,851,000 | $-83,993,000 |
| 2018 | $454.46 M | $336.48 M | $-115,184,000 | $-175,057,000 | $-175,149,000 |
| 2017 | $265.99 M | $186.79 M | $-98,823,000 | $-114,584,000 | $-114,397,000 |
| 2016 | $99.38 M | $54.18 M | $-155,489,002 | $-167,211,000 | $-167,211,000 |
| 2015 | $39.44 M | $14.94 M | $-150,047,005 | $-157,803,000 | $-157,803,000 |
| 2014 | $1.8 M | $-2,527,000 | $-96,287,000 | $-100,048,000 | $-100,048,000 |
| 2013 | $4.14 M | $4.14 M | $-45,027,000 | $-46,514,000 | $-46,514,000 |
| 2012 | $4.14 M | $4.14 M | $-51,395,000 | $-52,421,000 | $-52,421,000 |
| 2011 | $4.16 M | $4.14 M | $-28,254,000 | $-28,675,000 | $-28,675,000 |
| 2010 | $5.34 M | $5.32 M | $-11,326,000 | $-11,556,000 | $-11,556,000 |
| 2009 | $4.76 M | $4.74 M | $-9,075,000 | $-9,128,000 | $-9,089,000 |
| 2008 | $-867,000 | $-868,000 | $-8,745,000 | $-9,741,000 | $-9,741,000 |
| 2007 | $2.94 M | $1.75 M | $-12,847,000 | $-11,959,000 | $-11,959,000 |
| 2006 | $4.75 M | $3.94 M | $-14,167,000 | $-12,915,000 | $-12,915,000 |
| 2005 | $4.25 M | $3.68 M | $-15,634,000 | $-14,520,000 | $-14,520,000 |
| 2004 | $4.94 M | $4.45 M | $-19,195,000 | $-18,523,000 | $-18,523,000 |
| 2003 | $2.9 M | $2.88 M | $-28,838,000 | $-28,340,000 | $-28,340,000 |
| 2002 | $897 K | $888 K | $-28,687,000 | $-29,883,000 | $-29,883,000 |
| 2001 | $50.87 K | $50.87 K | $-25,133,000 | $-23,485,425,000 | $-23,485,425 |
| 2000 | $1 | $404.14 K | $-9,742,000 | $-13,329,822 | $-11,883,119 |
| 1999 | $ | $ | $-4,838,659 | $ | $-4,963,925 |
| 1998 | $ | $ | $-4,021,000 | $ | $-3,578,000 |